@talon_hrt's TRT cheat sheet claims, fact-checked

What did @talon_hrt actually say?

The video bills itself as a TRT starter guide, covering starting doses, injection sites, needle size, blood markers, frequency, duration, fertility risks, and where to get testosterone prescribed. The creator says a starting dose is "typically no more than 200 milligrams," recommends the deltoid, quad, and ventroglute as injection sites, suggests a 27-gauge half-inch needle, lists hematocrit, lipids, estradiol, CMP, and PSA as key labs, and states that TRT "is supposed to be for life." They also claim testosterone-related infertility "is extremely rare" and that fertility protocols can restore it even during TRT. The video ends with a direct plug for TalonWellness.com.

On the surface, a lot of this is reasonable basic information. But several claims are either imprecise enough to mislead new patients or flat-out wrong in ways that matter clinically.

Does the science back this up?

Mostly, but with meaningful gaps. The injection site recommendations are solid and consistent with standard intramuscular and subcutaneous practice. The blood marker list is legitimate, though incomplete. The infertility claim, however, is where things fall apart the most.

On injection sites: the deltoid (shoulder), vastus lateralis (outer quad), and ventroglute are all well-established IM sites supported by clinical nursing and urology literature. No argument there.

On the needle gauge: a 27-gauge half-inch needle is appropriate for subcutaneous injection, which is increasingly common for testosterone cypionate. But for true intramuscular injection into the ventroglute or quad, most clinical guidelines recommend a longer needle, typically 1 to 1.5 inches depending on body composition. A half-inch needle into the ventroglute of a larger patient may not reach muscle at all. The Endocrine Society's clinical practice guidelines (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism) do not endorse 27-gauge half-inch as a universal standard for IM testosterone.

On infertility: saying it is "extremely rare" is the most problematic claim in the video. The evidence says otherwise.

What did they get wrong (or right)?

The infertility claim is the biggest problem here. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, which dramatically reduces intratesticular testosterone and shuts down spermatogenesis. This is not rare, it is the expected physiological response. Turek et al. (2013, Fertility and Sterility) documented severe oligospermia or azoospermia in a significant proportion of men on exogenous testosterone. Calling this "extremely rare" could lead men who want future biological children to start TRT without understanding the real risk.

The creator is right that fertility protocols, typically using human chorionic gonadotropin (hCG), clomiphene, or FSH, can help preserve or restore fertility. That part is accurate and supported by literature (Wenker et al., 2015, Journal of Urology). But pairing a false "extremely rare" framing with the solution undermines the informed consent men need before starting.

What they got right: the blood marker list is genuinely useful. Tracking hematocrit, hemoglobin, and red blood cell count matters because testosterone raises erythropoiesis and can increase clotting risk at high hematocrit levels. Estradiol monitoring is legitimate. PSA monitoring for men over 40 is standard. Twice-weekly injections being sufficient is consistent with pharmacokinetic data on testosterone cypionate and enanthate.

What should you actually know?

If you are considering TRT, this video is a reasonable starting point but not a clinical roadmap. A few things worth knowing that the video skips or minimizes.

• Spermatogenesis suppression from exogenous testosterone is common, not rare. If having biological children is a future possibility, discuss fertility preservation before you start, not after.
• The "no more than 200 mg" starting dose framing is vague. Appropriate starting doses vary based on lab values, symptoms, age, and route of administration. That decision belongs with a physician who has reviewed your bloodwork, not a TikTok video.
• Needle selection depends on your body composition and injection route. Subcutaneous injections with shorter needles are increasingly used and have reasonable bioavailability data, but your provider should guide that choice.
• "For life" is accurate for men with true hypogonadism. But TRT initiated for optimization without a confirmed low testosterone diagnosis is a different clinical scenario with a different risk-benefit calculation.
• The lab panel mentioned is a starting point, not a complete picture. Depending on your history, providers may also track SHBG, free testosterone, thyroid function, and cardiovascular markers more broadly.

The bottom line: the creator is not spreading dangerous misinformation across the board, but the infertility claim is wrong in a way that could affect real decisions, and the needle guidance is imprecise enough to cause injection errors.